COVID-19 and Ebola Reclassification as Novel Acute Immune Deficiency Syndrome (n-AIDS): Potential Curative Role for Immunomodulators.

Abstract

SARS CoV-2, SARS, and MERS, the three highly contagious and relatively fatal coronaviruses which have evolved in only two decades and are anticipated to be joined by others, as well as the highly fatal Ebola virus disease have both similarities and differences to human immune deficiency virus (HIV) and its acquired immune deficiency syndrome (AIDS). In this manuscript, a suggested reclassification of COVID-19, Ebola, SARS, and MERS to be considered as a novel acute onset immune deficiency / immune dysrhythmic syndrome (n-AIDS) is provided aiming at a better quest for exploration of potential curative immunomodulators.

SARS CoV-2 Might Exploit Cells of the Innate Immune System to Induce the Novel Acute Immune Dysrhythmic Syndrome (n-AIDS) and Para COVID-19 Syndrome.

“…Importantly, we have recently suggested in a preprint that COVID-19, and other selected potentially fatal viral diseases, might be reclassified under a category of as immunopathological novel acute immune deficiency/ dysrhythmic Syndrome (n-AIDS) (Kelleni, 2021, March 25) and we have previously described an immunological monocytic dysrhythmia that plays a crucial role in development of the cytokine storm in another preprint that has been revised and is currently under consideration at a reputable journal (Kelleni, 2021, January 24) while suggesting further investigations for a potential latency of SARS CoV-2 in some of the immune system cells especially the migrating interstitial macrophages (Kelleni, 2021, March 25). Notably, we have previously postulated lymphocyte distraction into and/or away from the lungs to reason for the lymphopenia frequently encountered in COVID-19 and previously with SARS and we would like to present a combined theory to reason for COVID-19 pathogenesis especially in severe to critical cases that might also be determined, at least partly, on a genetic basis (Kelleni, 2021, January 19a).…”